Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer

Ishida,Koko; Hirose,Takashi; Yokouchi,Junichi; Oki,Yasunari; Kusumoto,Sojiro; Sugiyama,Tomohide; Ishida,Hiroo; Shirai,Takao; Nakashima,Masanao; Yamaoka,Toshimitsu; Ohnishi,Tsukasa; Ohmori,Tohru; Kagami,Yoshikazu

doi:10.3892/mco.2014.252

Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer

Authors:
- Koko Ishida
- Takashi Hirose
- Junichi Yokouchi
- Yasunari Oki
- Sojiro Kusumoto
- Tomohide Sugiyama
- Hiroo Ishida
- Takao Shirai
- Masanao Nakashima
- Toshimitsu Yamaoka
- Tsukasa Ohnishi
- Tohru Ohmori
- Yoshikazu Kagami
View Affiliations

Affiliations: Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Tokyo 142-8666, Japan, Department of Respirology, National Hospital Organization, Tokyo Hospital, Tokyo 204-8585, Japan, Department of Radiology, Showa University School of Medicine, Shinagawa, Tokyo 142-8666, Japan, Institute of Molecular Oncology, Showa University School of Medicine, Shinagawa, Tokyo 142-8666, Japan
Published online on: February 7, 2014 https://doi.org/10.3892/mco.2014.252
Pages: 405-410

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with non‑small cell lung cancer (NSCLC) have locally advanced disease with poor prognosis. Although concurrent chemoradiotherapy is the standard treatment, more effective regimens are required. The aim of this study was to assess the safety and efficacy of concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine in patients with locally advanced NSCLC. Patients with unresectable, stage IIIA or IIIB NSCLC were eligible for enrollment if they exhibited a performance status of 0‑2 and were ≤75 years of age. Patients were treated with carboplatin at an area under the plasma concentration vs. time curve of 2.5 mg̸ml̸min and vinorelbine at 20 mg/m2 on days 1 and 8 every 3 weeks. Thoracic radiotherapy at a total dose of 60 Gy was concurrently administered (2 Gy per fraction). Twenty‑eight patients (23 men and 5 women; median age, 67 years; range 47-75 years) were enrolled in the present study. The overall response rate was 85.7% [95% confidence interval (CI), 67.3‑96.0%] and the disease control rate was 96.4% (95% CI, 81.7‑99.9%). The median survival time (MST) was 23 months and the median progression‑free survival (PFS) time was 8 months. Grade 3‑4 toxicities included neutropenia, thrombocytopenia, anemia and infection in 100, 14, 46 and 36% of patients, respectively. One patient (4%) developed grade 3 radiation esophagitis that resolved completely without residual dilation. Grade 3 radiation pneumonitis occurred in 2 patients (7%); however, the symptoms and radiographic abnormalities subsided with corticosteroid therapy. In conclusion, concurrent chemoradiotherapy with a divided schedule of carboplatin and vinorelbine is well‑tolerated and effective in patients with locally advanced NSCLC.

View Figures

View References

1.	Goldstraw P, Crowley J, Chansky K, et al: International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASCL Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007.
2.	Auperin A, Le Pechoux C, Pignon JP, et al: Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 17:473–483. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Auperin A, Le Pechoux C, Rolland E, et al: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 28:2181–2190. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Vokes EE, Herndon JE II and Crawford J: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 20:4191–4198. 2002. View Article : Google Scholar
5.	Go RS and Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 17:409–422. 1999.PubMed/NCBI
6.	Yamamoto N, Nakagawa K, Nishimura Y, et al: Phase III study comparing second-and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 28:3739–3745. 2010. View Article : Google Scholar
7.	Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M and Tanimoto M: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 22:3852–3859. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Ardizzoni A, Boni L, Tiseo M, et al: Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 99:847–857. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Douple EB, Richmond RC, O’Hara JA and Coughlin CT: Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev. 12:111–124. 1985. View Article : Google Scholar
10.	Edelstein MP, Wolfe LA III and Duch DS: Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol. 23:41–47. 1996.PubMed/NCBI
11.	Riedel RF, Andrews C, Garst J, et al: A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. J Thorac Oncol. 2:520–525. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Bretti S, Manzin E, Celano A, Ritorto G, Loddo C and Berruti A: Low-dose carboplatin (AUC4.5) combined with vinorelbine in the treatment of advanced non-small cell lung cancer: A single institution phase II study. Oncol Rep. 8:381–385. 2001.PubMed/NCBI
13.	Hoffman PC, Cohen EE, Masters GA, et al: Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 38:65–71. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Edelman MJ, Suntharalingam M, Burrows W, et al: Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg. 86:903–911. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Masters GA, Hahn EA, Shevrin DH and Kies MS: Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer. Lung Cancer. 39:221–226. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Zatloukal P, Petruzelka L, Zemanova M, et al: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer. 46:87–98. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Segawa Y, Kiura K, Takigawa N, et al: Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesin, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 28:3299–3306. 2010. View Article : Google Scholar
18.	Hanna N, Neubauer M, Yiannoutsos C, et al: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 26:5755–5760. 2008. View Article : Google Scholar
19.	Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel con4=8solidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 26:2450–2456. 2008.
20.	Spigel DR, Hainsworth JD, Yardley DA, et al: Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 28:43–48. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesin, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:2692–2699. 1999.
22.	Haasbeek CJ, Slotman BJ and Senan S: Radiotherapy for lung cancer: clinical impact of recent technical advances. Lung Cancer. 64:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Gould MK, Kuschner WG, Rydzak CE, et al: Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer. Ann Intern Med. 139:879–892. 2003. View Article : Google Scholar : PubMed/NCBI
24.	Birim O, Kappetein AP, Stijnen T and Bogers AJ: Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in non-small cell lung cancer. Ann Thorac Surg. 79:375–381. 2005. View Article : Google Scholar : PubMed/NCBI
25.	Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J and Silvestri GA: American College of Chest Physicians. Invasive mediastinal staging of lung cancer: AACP evidence-based clinical practice guidelines (2nd Edition). Chest. 132:S202–S220. 2007. View Article : Google Scholar : PubMed/NCBI